Keyphrases
Renal Cell Carcinoma
83%
Radical Nephrectomy
75%
Gender Differences
66%
Systemic Therapy
66%
Radical Cystectomy
58%
Minimally Invasive
58%
Genitourinary Injury
50%
Small Renal Mass
50%
Active Surveillance
50%
Young Patients
50%
Clinical Management
50%
Delayed Intervention
50%
Lower Urinary Tract Symptoms
50%
Geriatric Patients
50%
Metastatic Renal Cell Carcinoma (mRCC)
50%
Post-stroke
50%
Kidney-sparing Surgery
50%
Testis-sparing Surgery
50%
Radical Cystectomy in Women
50%
Sarcomatoid Urothelial Carcinoma
50%
Overall Survival
50%
Incontinence
50%
Carcinosarcoma
50%
Prostate
50%
Stress Urinary Incontinence
50%
Bacillus Calmette-Guérin
50%
Upper Tract Urothelial Cancer
50%
Endoscopic Management
50%
Variant Histology
50%
Healthcare Applications
50%
Delirium in Elderly
50%
Sarcomatoid Carcinoma
50%
Elderly Subjects
50%
Volume-outcome Relationship
50%
Postoperative Delirium
50%
Overweight Men
50%
Reproductive Organs
50%
Urological Surgery
50%
Nonsurgical Options
50%
Advanced Stage
50%
Mitomycin C
50%
Kidney Preservation
50%
Tumor
50%
Knee Arthroplasty
50%
Single Institution
50%
Clear Cell Renal Cell Carcinoma (ccRCC)
50%
Weight Management Program
50%
Length of Stay
50%
Tumor Thrombus
50%
Patient Risk
50%
Medicine and Dentistry
Clear Cell Renal Cell Carcinoma
100%
Cystectomy
100%
Transitional Cell Carcinoma
100%
Neoplasm
89%
Diseases
82%
Radical Nephrectomy
61%
Genitourinary Trauma
50%
Urologic Surgery
50%
Clinical Management
50%
Reproductive Organ
50%
Testes
50%
Tumor Thrombus
50%
Lower Urinary Tract Symptom
50%
Surgeon
50%
Apoplexy
50%
Health Care
50%
Sex Difference
50%
Geriatrics
50%
Reactive Oxygen Species
50%
Kidney Tumour
50%
Kidney Cancer
50%
Sarcomatoid
50%
Incontinence
50%
Upper Urinary Tract
50%
Urothelial Cancer
50%
Kidney Preservation
50%
Stress Incontinence
50%
Mycobacterium Bovis BCG
50%
Mitomycin
50%
Urological Procedure
50%
Recurrent Disease
47%
Logistic Regression Analysis
46%
Conservative Treatment
41%
Odds Ratio
41%
Ureteroscopy
41%
Accelerometer
37%
Vital Sign
37%
Carcinosarcoma
33%
Inferior Vena Cava
33%
Sarcomatoid Carcinoma
33%
Metastatic Carcinoma
33%
Recurrence Free Survival
28%
Cancer Specific Survival
28%
Overall Survival
28%
Intracavitary Therapy
25%
Narrow Band Imaging
25%
Systemic Therapy
25%
Fulguration
25%
Nephron
25%
Nephroureterectomy
25%
